Outcome Data:
The median time to the first of two consecutive negative tests in our cohort by KM analysis was 42 days (IQR 25.0-55.0), and 11 of the 68 children (16%) had intermittent negative followed by positive results (Figure 1).
Children with an oncologic diagnosis had a longer median time to two consecutive negative tests compared with children receiving other immunocompromising medications (38.0 [IQR 25.0-55.0] vs 30.0 [IQR 21.0-44.0] days), but these findings were not statistically significant (p = 0.097) (Table 1). KM analysis which included the censored subjects also showed there was no difference in times to two consecutive negative tests between these groups (Figure 2, log rank p=0.88). KM analyses demonstrated that children with leukemia and lymphoma had a longer time to negative testing (43 days, IQR 25,55), versus children with a solid tumor diagnosis (35 days [IQR 26,50], log rank p = 0.33) (Figure 3). Children with low ALC (<1000 cells/uL) had longer time to negative testing (44 days, IQR 25,55) days compared with those with a moderately low to normal ALC (31 [IQR 26-44] days), log rank p = 0.17. There was no statistically significant difference between time to negative testing for children with symptomatic vs asymptomatic illness (42 [IQR 30-55] vs 38 [IQR 22-55] days, log rank p = 0.59).